Peoples Rx recently held a free, live webinar providing insight into the science, physiology and mechanisms of action of LDN, as well as the many conditions that it may benefit. LDN is ONLY available by compounded prescription.

Individuals who suffer from symptoms of gastrointestinal, autoimmune, dermatological and pain conditions make up 80% of the patient population. The potential benefits of LDN with its low incidence of side effects, low risk of toxicity, and good clinical efficacy make LDN a good choice to try for managing chronic autoimmune conditions and inflammation. Low-dose naltrexone (LDN) has been studied recently in many conditions.

Conditions That May Benefit From Using Compounded LDN Include:

  • Fibromyalgia
  • Hashimoto’s Disease
  • Crohn’s Disease
  • Lyme Disease (LATE Stage)
  • Chronic Fatigue Syndrome
  • Irritable Bowel Syndrome (IBS)
  • Rheumatoid Arthritis
  • Systemic Lupus (SLE)
  • Ulcerative Colitis
  • Multiple Sclerosis (MS)
  • Alzheimer’s Disease
  • Post-Traumatic Stress Disorder (PTSD)
  • Autism Spectrum Disorder
  • Parkinson’s Disease
  • Depression (Major; Bipolar)
  • Emphysema (COPD)
  • Psoriasis and Eczema
  • Women’s Health (PCOS, Endometriosis, Pelvic Pain)
  • Cancer

LDN may be helpful to anyone who has an autoimmune disease and/or chronic pain. Research shows that LDN can normalize the immune system and limit the progression of an autoimmune attack due to the increase in endorphins. (Endorphins are the body’s endogenous opiates that act to reduce the perception of pain, regulate cell growth, and regulate the immune system.) The increased endorphin levels result in reduced inflammation leading to decreased pain sensitivity, reduced fatigue, and less cognitive disruption.

For more information on LDN, including a list of physicians who specialize in this treatment, please contact our Peoples Rx Compounding Center at 512-646-4007 or email


**This article is not intended to be medical advice. Please consult your healthcare practitioner before use.**

If you have comments and/or questions about this blog, email us at